Corbus Pharmaceuticals Holdings Inc Stock News

NORWOOD, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today the dosing of the first subject in the single ascending dose / multiple ascending dose (SAD/MAD) portion of the Phase 1 trial of CRB-913 for the treatment of obesity. The study is being ...

NORWOOD, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) (“Corbus” or the “Company”), announced that data from its US and UK conducted first-in-human dose escalation clinical study (“Western study”) of CRB-701 (SYS6002) is being presented today at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).

NORWOOD, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States and Europe (“Western study”) of CRB-701 (SYS6002) has been released. The corresponding up-to-date data will be presented as a poster during the 20...

NORWOOD, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be participating in the Guggenheim SMID Cap Biotech Conference, to be held February 5-6, 2025 in New York, NY Dr. Cohen will participate in analyst led fireside discussion and will att...

NORWOOD, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be participating in the 43rd Annual J.P. Morgan Healthcare Conference, to be held January 13-16, 2025 in San Francisco, CA. Dr. Cohen will be presenting and attending investor meetings.

CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environment CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environment

NORWOOD, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CRB-701 for the treatment of relapsed or refractory metastatic cervical cancer. CRB-701 (SYS6002) is...

Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials and CRB-913 targeting obesity with potentially fewer CNS side effects. Despite early-stage pipeline risks, CRBP's recent sell-off offers a favorable entry point for speculative investors, upgrading my rating from "Hold" to "Speculative Buy." CRBP's valuation is compelling with $159.4 million in liq...